SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is undergoing a massive, volatile short squeeze that has left the community debating if the rally is a sustained mechanical dislocation or a house of cards nearing a blow-off top. Investors are actively discussing the stock's extreme short interest and low float relative to institutional ownership, with many monitoring for a potential secondary offering or sudden reversal while debating whether to jump in, hold, or short against the parabolic trend.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is currently capturing attention as the community weighs the company's long-term potential in deep-sea mining against regulatory and geopolitical headwinds. Investors are actively debating the impact of upcoming production milestones and the necessity of US-based mineral sourcing, while closely monitoring institutional activity and options volume for signs of a potential short squeeze.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors debate its long-term potential following recent regulatory approvals and strategic expansion efforts. While some in the community highlight the stock's significant upside from new institutional partnerships and infrastructure contracts, others express deep frustration with management's communication, the lack of formal earnings guidance, and ongoing concerns regarding dilution.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is experiencing heightened volatility and intense retail debate as traders weigh significant insider purchasing by CEO Jeff Green against ongoing concerns regarding market sentiment and recurring negative media reports. Community members are actively speculating on potential partnerships and monitoring technical support levels while navigating sharp price swings that have fueled intense discussion about the stock's long-term valuation versus its recent performance.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is surging as investors react to a new executive order prioritizing the expedited FDA review and funding of psychedelic drugs, particularly ibogaine. The community is actively debating the stock's potential for a short squeeze due to its small float and limited share supply, with many retail traders focusing on the company's status as a GMP-compliant supplier amid the shift in regulatory sentiment.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant volatility after a Blue Origin launch mishap left its satellite in an unusable, low orbit, fueling debates about launch provider reliability and near-term deployment delays. Despite the setback, the community remains intensely divided, with many long-term investors viewing the dip as a high-conviction buying opportunity supported by insurance coverage and robust, intact business fundamentals, while bearish traders point to execution risks and potential cash burn concerns.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending amid a surge in sector momentum and investor excitement following a strategic partnership with French rare-earth processor Carester, which aims to shorten the supply chain gap. The community is actively debating the stock's long-term potential as a vertically integrated domestic leader versus short-term risks like potential share dilution and sensitivity to geopolitical tensions.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is experiencing significant volatility driven by intense community debate over its sudden, parabolic price swings, which many traders are labeling as a classic pump-and-dump scheme. While some investors are actively scalping the momentum, others are highlighting concerns about the company's obscure business model and the heavy influx of bot-like activity on social platforms.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark Inc is experiencing significant social media debate as investors remain divided over the company's long-term potential, specifically weighing its bitcoin mining operations against the anticipation of a major AI data center partnership. While some community members maintain bullish conviction citing strategic infrastructure and mining metrics, others are expressing frustration over the lack of a formal AI deal and executive compensation practices.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing increased investor attention and positive price momentum, driven by speculation over a potential buyout as the company nears key performance incentive deadlines. Traders are also closely monitoring expanded share buybacks and strong patient adoption data for Briumvi, fueling community optimism about the stock's long-term valuation and upcoming data catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research.</li><li>The company emphasized Tasimelteon’s well-established safety profile.&nbsp;</li><li>The company had recently received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting.</li></ul>Shares of Vanda Pharmaceuticals Inc. (VNDA) fell 10% in premarket trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) stated that its supplemental New Drug Application for HETLIOZ (tasimelteon) to treat jet lag disorder cannot be approved in its current form.While the FDA acknowledged positive results from Vanda’s clinical trials, it cited concerns that the controlled phase-advance protocols used in the studies do not fully replicate real-world jet travel conditions, including reduced oxygen pressure, noise, and lighting changes.Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research and effectively simulate core jet-lag symptoms. The company emphasized tasimelteon’s well-established safety profile and demonstrated benefits on sleep and next-day alertness.This comes after the company received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting on December 31, 2025.The FDA approval marked the first new pharmacologic treatment for motion sickness in more than 40 years. Vanda expects to launch NEREUS in the coming months. Beyond motion sickness, Vanda is advancing tradipitant in clinical development for other conditions driven by similar pathways, including gastroparesis and nausea linked to GLP-1 therapies.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits turned 'bullish' from 'neutral' a day earlier.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/VNDA_jpg_66bd88803d.webp" alt="VNDA.jpg" width="922" height="88"><figcaption>&nbsp;</figcaption></figure>One bullish user sees strong buy at this level, stating that the motion sickness drug approval is a much bigger news than today's update.<stembedurl>https://stocktwits.com/pablo4/message/641232419</stembedurl>Over the past one year, <a href="https://stocktwits.com/symbol/VNDA">VNDA shares</a> have gained around 52%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application

The FDA cited concerns that the controlled phase advance protocols used in studies do not fully replicate real-world jet travel conditions.

Equity

<ul class="summary-bullets"><li>The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026.</li><li>U.S. FDA had approved Ironwood’s Linzess capsules for pediatric patients, in November.</li><li>Linzess is the first treatment approved for the irritable bowel syndrome with constipation in pediatric patients.</li></ul>Shares of Ironwood Pharmaceuticals (<a href="https://stocktwits.com/symbol/IRWD">IRWD</a>) jumped more than 38% in premarket trading on Friday after its FY2026 guidance came in above expectations, boosted by higher sales of its drug Linzess, which is used to treat constipation.The biotechnology company said it expects FY2026 revenue in the range of $450 million to $475 million, higher than analyst expectations of $319.5 million, according to data from Fiscal.ai.&nbsp;The outlook assumes net sales of Linzess will be between $1.125 billion and $1.175 billion in FY2026, driven by improved net price and low-single-digit demand growth, the company said.&nbsp;“We believe our full-year 2026 guidance demonstrates the significant progress we’ve made to deliver on these priorities to help drive value for shareholders moving forward,” it stated.&nbsp;<h2 class="st-heading-2">Linzess’ Potential</h2>In November, the U.S. Food and Drug Administration approved Ironwood’s Linzess capsules for pediatric patients aged seven and older with irritable bowel syndrome with constipation.Linzess is the first treatment approved for the disease in pediatric patients, the FDA had said at the time. Irritable bowel syndrome with constipation (IBS-C) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain associated with infrequent, hard-to-pass stools. The contributing factors to the condition are typically multiple.Linzess is already approved for the treatment of adult patients with the condition. The FDA had noted that the safety and efficacy of Linzess were similar in clinical studies for both adults and pediatric patients.“Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming quarters,” said Tom McCourt, chief executive officer of Ironwood. “We expect higher net sales in 2026 for LINZESS year-over-year,” he added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:632/64;" src="https://news.stocktwits-cdn.com/irwd_2_PNG_f7f4732ebe.webp" alt="Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes. " width="632" height="64"></figure>One user wondered whether the stock will hit the $10 mark.&nbsp;<figure class="image"><img style="aspect-ratio:667/154;" src="https://news.stocktwits-cdn.com/irwd_PNG_26af83bb21.webp" alt="One user wondered whether the stock will hit the $10 mark. " width="667" height="154"></figure>&nbsp;Shares in the IRWD fell 25.1% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

The Linzess Room at Ironwood Pharmaceuticals in Cambridge, MA on April 20, 2018. (Photo by Craig F. Walker/The Boston Globe via Getty Images)

Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?

The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range. 

SMLV
SPDR SSGA US Small Cap Low Volatility Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SMLV News

SMLVSPDR SSGA US Small Cap Low Volatility Index ETF